Filter News
Area of Research
- (-) Isotopes (5)
- (-) Nuclear Science and Technology (2)
- Biological Systems (1)
- Biology and Environment (24)
- Clean Energy (76)
- Computational Biology (2)
- Computational Engineering (1)
- Computer Science (4)
- Fusion and Fission (3)
- Fusion Energy (1)
- Materials (33)
- Materials for Computing (10)
- National Security (7)
- Neutron Science (26)
- Quantum information Science (9)
- Supercomputing (80)
- Transportation Systems (2)
News Topics
- (-) Biomedical (7)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (11)
- Bioenergy (1)
- Climate Change (1)
- Computer Science (3)
- Coronavirus (1)
- Cybersecurity (1)
- Decarbonization (1)
- Energy Storage (1)
- Environment (2)
- Fusion (8)
- Irradiation (1)
- Isotopes (29)
- Materials (4)
- Materials Science (5)
- Molten Salt (4)
- National Security (1)
- Neutron Science (5)
- Nuclear Energy (39)
- Physics (2)
- Security (1)
- Space Exploration (9)
- Sustainable Energy (1)
- Transformational Challenge Reactor (3)
Media Contacts
Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.
Researchers at ORNL explored radium’s chemistry to advance cancer treatments using ionizing radiation.
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.